On March 7, 2023, at the invitation of Professor Dalei Wu, Dr. Kuifeng Wang, the founder and CEO of QinHao Pharmaceuticals, gave the first lecture of the course “Introduction to the Biomedical and Pharmaceutical Industry” in Room S313 of ZhenShengYuan. The theme of this lecture was “Review and Reflection on China’s Biomedical Industry in 2022”.

Dr. Wang first provided a comprehensive overview of the new drug development process, highlighting key stages such as drug discovery, pharmaceutical research, preclinical studies, and approval for marketing. He then elaborated on the development history of modern Chinese pharmacology, the opportunities and challenges it faces, and the country’s recent pharmaceutical policies. As a leading figure in the biomedical industry, Dr. Wang also analyzed the current state of investment and financing in the industry over the past five years and made predictions about the future development environment. He stated that the industry is currently undergoing an adjustment period, and after this adjustment, truly capable projects and enterprises will stand out and be more favored by capital, thus ushering in a new stage of development for China’s innovative drug industry.

At the end of the lecture, teachers and students from the Institute actively raised questions based on their thoughts and concerns from the report. Dr. Wang answered each question in detail and shared his entrepreneurial experience for the students to learn from and draw upon. Finally, Dr. Wang shared four valuable experiences he had accumulated during his learning and entrepreneurial journey. First, one must have an adventurous spirit and be willing to do difficult but correct things. Second, maintain a positive and optimistic attitude. On the one hand, one should be optimistic when facing experimental failures in scientific research; the more setbacks and challenges one encounters, the stronger the resilient qualities one will develop. On the other hand, one should firmly believe that the future of biomedicine is full of infinite possibilities because clinical demands can never be fully met. Third, never complain and learn to look for problems within oneself first. Fourth, one must have an extraordinary level of persistence.

During this lecture, Dr. Wang’s refined demeanor, meticulous logic, and profound knowledge left a deep impression on everyone. He delivered a very rich and insightful report on the progress and trends of the biopharmaceutical industry, providing significant assistance to students in their basic research, internships, practical experiences, and career choices, and further broadening their horizons. After the lecture, students expressed that they had gained a lot and were very satisfied.

Dr. Wang’s Profile

Dr. Kui Feng Wang graduated from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He is the CEO of QinHao Pharmaceuticals (Suzhou), a founding member of the Science and Technology Innovation Enterprise Branch of the Zhejiang University Alumni Association, a visiting professor at Soochow University, a board member of Nanjing University of Chinese Medicine, a specially-appointed researcher at the Taizhou Hospital Affiliated to Wenzhou Medical University, a national “Ten Thousand Talents Program” leading talent, and has been selected for the Ministry of Science and Technology’s Innovation Talent Promotion Program for Innovation and Entrepreneurship Talents, Jiangsu Province’s “Double Innovation Program” for Innovation and Entrepreneurship Talents, Jiangsu Province’s “Six Major Talent Peaks”for High-level Talents, Suzhou City’s Young Entrepreneur Star, the High-level Leading Talent of the Jinji Lake Talent Program, and the Leading Talent of Suzhou Industrial Park’s Science and Technology. He is also a special invited executive director of the Jiangsu Biotechnology Association.

Company Profile

Qinhao Pharmaceuticals was established in 2014, dedicated to breaking through “undruggable” targets, focusing on original innovation, and developing new small molecule anti-tumor drugs. Currently, the company has formed a product pipeline centered on targeted anti-tumor varieties. Among them, three products have entered the clinical development stage, and one product has successfully achieved “license-out” authorization. In addition, several products in the company’s 2.0 pipeline project are about to enter the IND application stage. Since its establishment, Qinhao Pharmaceuticals has also received the favor of many capital investors. Currently, the company has completed multiple rounds of financing amounting to hundreds of millions of yuan, with investors including China Capital, Lingcheng Venture Capital, Viva Biotech, Yueyin Medical Fund, Hengbo Tongzhou, Legend Star, Sanhua Hongdao, Qian Dao Fund, Panyi Investment, and Guohai Innovation Capital, among others.